HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A double-blind vehicle-controlled study of R 68 151 in psoriasis: a topical 5-lipoxygenase inhibitor.

Abstract
Recently the pharmacologic role of leukotrienes (LTs), especially that of LTB4, has been intensively investigated in psoriasis. In vitro, R 68 151 is a potent 5-lipoxygenase inhibitor and consequently reduces LTB4 formation. Therefore the role of an in vitro 5-lipoxygenase inhibitor and its clinical use in psoriasis were evaluated with topical R 68 151 in a double-blind vehicle-controlled study. Eighty-eight patients with localized psoriatic lesions were treated twice daily with R 68 151 2% ointment (n = 44) or vehicle ointment (n = 44) during 4 weeks. Most patients (n = 73) had psoriasis vulgaris (n = 37, R 68 151; n = 36, vehicle). In 27% of the R 68 151-treated patients with psoriasis vulgaris, the lesions disappeared or showed marked improvement, compared with 8% in the vehicle group (X2, p = 0.06). The scores in global evaluation, however, were significantly different between both treatment groups (p less than 0.05, Mann-Whitney U test). The improvement of the mean symptom score with R 68 151 was 46% for scaling and 34% for erythema at the end of the study compared with an improvement of 6% and a deterioration of 3%, respectively, in the control group (p less than 0.05, p less than 0.01; Mann-Whitney U test). The global evaluation in the total group of patients with psoriasis (all different subtypes) was consistent with the response rate in the group of patients with psoriasis vulgaris: 30% in the test group versus 11% in the control group (X2, p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
AuthorsH Degreef, P Dockx, P De Doncker, K De Beule, G Cauwenbergh
JournalJournal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 22 Issue 5 Pt 1 Pg. 751-5 (May 1990) ISSN: 0190-9622 [Print] United States
PMID2189906 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Imidazoles
  • Lipoxygenase Inhibitors
  • Pharmaceutical Vehicles
  • Piperazines
  • R 68151
  • Arachidonate Lipoxygenases
  • Arachidonate 5-Lipoxygenase
Topics
  • Administration, Cutaneous
  • Adolescent
  • Adult
  • Aged
  • Arachidonate 5-Lipoxygenase (administration & dosage, adverse effects, therapeutic use)
  • Arachidonate Lipoxygenases (antagonists & inhibitors)
  • Double-Blind Method
  • Female
  • Humans
  • Imidazoles
  • Lipoxygenase Inhibitors
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Pharmaceutical Vehicles
  • Piperazines
  • Psoriasis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: